Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Viking Therapeutics (VKTX) over the last 12 years, with Q4 2025 value amounting to $165.8 million.

  • Viking Therapeutics' Cash & Equivalents rose 52157.0% to $165.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was $165.8 million, marking a year-over-year increase of 52157.0%. This contributed to the annual value of $165.8 million for FY2025, which is 52157.0% up from last year.
  • Latest data reveals that Viking Therapeutics reported Cash & Equivalents of $165.8 million as of Q4 2025, which was up 52157.0% from $100.4 million recorded in Q3 2025.
  • In the past 5 years, Viking Therapeutics' Cash & Equivalents registered a high of $195.6 million during Q1 2024, and its lowest value of $8.8 million during Q2 2021.
  • For the 5-year period, Viking Therapeutics' Cash & Equivalents averaged around $64.8 million, with its median value being $37.6 million (2023).
  • In the last 5 years, Viking Therapeutics' Cash & Equivalents surged by 162942.58% in 2022 and then plummeted by 8971.92% in 2023.
  • Over the past 5 years, Viking Therapeutics' Cash & Equivalents (Quarter) stood at $26.4 million in 2021, then soared by 38.91% to $36.6 million in 2022, then surged by 51.55% to $55.5 million in 2023, then plummeted by 51.95% to $26.7 million in 2024, then surged by 521.57% to $165.8 million in 2025.
  • Its Cash & Equivalents was $165.8 million in Q4 2025, compared to $100.4 million in Q3 2025 and $33.9 million in Q2 2025.